TLIS Stock Overview
Operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Talis Biomedical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.70 |
| 52 Week High | US$9.60 |
| 52 Week Low | US$1.37 |
| Beta | 1.58 |
| 1 Month Change | 0.59% |
| 3 Month Change | -16.67% |
| 1 Year Change | -77.75% |
| 3 Year Change | -97.11% |
| 5 Year Change | n/a |
| Change since IPO | -99.59% |
Recent News & Updates
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14Shareholder Returns
| TLIS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.6% | -0.3% | -0.4% |
| 1Y | -77.7% | 10.5% | 24.8% |
Return vs Industry: TLIS underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: TLIS underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| TLIS volatility | |
|---|---|
| TLIS Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TLIS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TLIS's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rob Kelley | talisbio.com |
Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.
Talis Biomedical Corporation Fundamentals Summary
| TLIS fundamental statistics | |
|---|---|
| Market cap | US$3.10m |
| Earnings (TTM) | -US$51.03m |
| Revenue (TTM) | US$408.00k |
7.6x
P/S Ratio-0.1x
P/E RatioIs TLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIS income statement (TTM) | |
|---|---|
| Revenue | US$408.00k |
| Cost of Revenue | US$20.50m |
| Gross Profit | -US$20.09m |
| Other Expenses | US$30.94m |
| Earnings | -US$51.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.99 |
| Gross Margin | -4,923.77% |
| Net Profit Margin | -12,506.37% |
| Debt/Equity Ratio | 0% |
How did TLIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 03:02 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Talis Biomedical Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Tycho Peterson | J.P. Morgan |